Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. / Dollerup, Ole L.; Trammell, Samuel A.J.; Hartmann, Bolette; Holst, Jens J.; Christensen, Britt; Møller, Niels; Gillum, Matthew P.; Treebak, Jonas T.; Jessen, Niels.

I: The Journal of clinical endocrinology and metabolism, Bind 104, Nr. 11, 01.11.2019, s. 5703-5714.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Dollerup, OL, Trammell, SAJ, Hartmann, B, Holst, JJ, Christensen, B, Møller, N, Gillum, MP, Treebak, JT & Jessen, N 2019, 'Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity', The Journal of clinical endocrinology and metabolism, bind 104, nr. 11, s. 5703-5714. https://doi.org/10.1210/jc.2019-01081

APA

Dollerup, O. L., Trammell, S. A. J., Hartmann, B., Holst, J. J., Christensen, B., Møller, N., Gillum, M. P., Treebak, J. T., & Jessen, N. (2019). Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. The Journal of clinical endocrinology and metabolism, 104(11), 5703-5714. https://doi.org/10.1210/jc.2019-01081

Vancouver

Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N o.a. Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. The Journal of clinical endocrinology and metabolism. 2019 nov. 1;104(11):5703-5714. https://doi.org/10.1210/jc.2019-01081

Author

Dollerup, Ole L. ; Trammell, Samuel A.J. ; Hartmann, Bolette ; Holst, Jens J. ; Christensen, Britt ; Møller, Niels ; Gillum, Matthew P. ; Treebak, Jonas T. ; Jessen, Niels. / Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. I: The Journal of clinical endocrinology and metabolism. 2019 ; Bind 104, Nr. 11. s. 5703-5714.

Bibtex

@article{a7c167bb2ea84bbaa401f0740f3c5c1e,
title = "Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity",
abstract = "OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.",
author = "Dollerup, {Ole L.} and Trammell, {Samuel A.J.} and Bolette Hartmann and Holst, {Jens J.} and Britt Christensen and Niels M{\o}ller and Gillum, {Matthew P.} and Treebak, {Jonas T.} and Niels Jessen",
year = "2019",
month = nov,
day = "1",
doi = "10.1210/jc.2019-01081",
language = "English",
volume = "104",
pages = "5703--5714",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

AU - Dollerup, Ole L.

AU - Trammell, Samuel A.J.

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Christensen, Britt

AU - Møller, Niels

AU - Gillum, Matthew P.

AU - Treebak, Jonas T.

AU - Jessen, Niels

PY - 2019/11/1

Y1 - 2019/11/1

N2 - OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.

AB - OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.

UR - http://www.scopus.com/inward/record.url?scp=85073183847&partnerID=8YFLogxK

U2 - 10.1210/jc.2019-01081

DO - 10.1210/jc.2019-01081

M3 - Journal article

C2 - 31390002

VL - 104

SP - 5703

EP - 5714

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -

ID: 231301319